Pyrazino[2,3-b]pyrazine Modulators for RORγ Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and allergic disorders lack effective compounds that can inhibit RORγ with stable metabolic properties, necessary for achieving therapeutic levels.
Innovation Solution
Development of novel heteroaromatic compounds with specific structural formulas that exhibit potent inhibitory activity against RORγ, designed to possess metabolic stability and suitable pharmacokinetic properties for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for autoimmune and allergic disorders, then existing therapeutic options are available, but effective compounds that can inhibit RORγ with stable metabolic properties are lacking
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures (formula I with various substituents R1-R6, X, Y, W) to optimize both RORγ inhibitory activity and metabolic stability. By changing molecular parameters such as substituent types, positions, and configurations, the invention achieves compounds that simultaneously provide effective enzyme inhibition and improved pharmacokinetic properties including metabolic stability.
2Reliability
If compounds with potent RORγ inhibitory activity are developed, then therapeutic efficacy is improved, but metabolic stability and pharmacokinetic properties may be compromised
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions (R1 at position 1, R2 at position 2, R3 at position 3, etc.) on the core heteroaromatic structure. Each substituent is carefully selected to provide localized functional properties: some positions are optimized for RORγ binding affinity while others are designed for metabolic stability. This spatial differentiation of functional properties allows simultaneous achievement of therapeutic efficacy and metabolic stability.
Solution Approach 2:
The patent employs composite material principles by combining the core heteroaromatic structure (pyrazino[2,3-b]pyrazine or pyrazino[2,3-c]pyridazine) with various substituent moieties (aryl, heteroaryl, alkyl, cycloalkyl groups) to create composite molecular structures. These composite structures integrate the functions of different structural components, where the core provides RORγ binding capability and the substituents contribute to metabolic stability and pharmacokinetic properties.
Data Source
AI summary
The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.